As a major STAT5 target gene, its expression is strongly increased in a range of myeloproliferative disorders where STAT5 is activated, including BCR/ABL-induced CML (169) and JAK2 V617F-induced disease (170). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.